Rx Product News

Published Online: Monday, February 17, 2014
Follow Pharmacy_Times:


Brintellix

Marketed by: H. Lundbeck A/S and Takeda Pharmaceuticals America, Inc
Indication: The FDA has approved Brintellix (vortioxetine) for treating adults with major depressive disorder. The recommended starting dose is 10 mg orally once daily without regard to meals; the dose should then be increased to 20 mg/ day, as tolerated. Brintellix can be discontinued abruptly; however, it is recommended that doses of 15 or 20 mg/day be reduced to 10 mg/day for 1 week before full discontinuation.
Dosage Form: Immediate-release tablets: 5, 10, 15, and 20 mg
For More Information: www.us.brintellix.com




ADEMPAS
Marketed by:
Bayer HealthCare Pharmaceuticals, Inc
Indication: The FDA has approved Adempas (riociguat), a soluble guanylate cyclase stimulator, to treat adults with (1) persistent/ recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class or (2) pulmonary arterial hypertension to improve exercise capacity, improve WHO functional class, and delay clinical worsening. Treatment should be initiated at a dosage of 1 mg 3 times a day.
Dosage Form: Tablets: 0.5, 1, 1.5, 2, and 2.5 mg
For More Information: www.adempas-us.com





DUAVEE
Marketed by:
Pfizer
Indication: The FDA has approved Duavee (conjugated estrogens/bazedoxifene) for the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause and for the prevention of postmenopausal osteoporosis. The recommended dose is 1 tablet by mouth once daily. Women taking Duavee should not take additional estrogens. Duavee should be used for the shortest duration consistent with the treatment goals and risks for the individual female patient.
Dosage Form: Tablets (conjugated estrogens/bazedoxifene): 0.45 mg/20 mg
For More Information: www.pfizerpro.com/hcp/duavee



ADASUVE
Marketed by:
Teva Pharmaceuticals USA, Inc
Indication: Adasuve (loxapine) inhalation powder is a typical antipsychotic indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Adasuve must be administered only by a health care professional. Before administration, all patients must be screened for a history of pulmonary disease and examined for respiratory abnormalities. Only a single 10-mg dose of Adasuve should be administered within a 24-hour period, by oral inhalation using the single-use inhaler.
Dosage Form: Inhalation powder: 10 mg
For More Information: www.adasuve.com

Related Articles
The FDA has updated the label of Pfizer’s prescription smoking cessation agent, varenicline (Chantix), to warn about potential alcohol interaction and rare seizure risks.
A review of the evidence and possible explanations.
The FDA recently accepted for review New Drug Applications for Collegium Pharmaceuticals’ extended-release oxycodone formulation (Xtampza ER) and Pfizer’s extended-release oxycodone hydrochloride and naltrexone hydrochloride (ALO-02), a pair of opioid analgesics with abuse-deterrent properties.
Avella Specialty Pharmacy announced today that it has been selected by Pfizer as one of the limited groups of specialty pharmacies authorized to distribute the manufacturer’s breakthrough breast cancer drug—Ibrance (palbociclib)—which has just received fast-tracked approval from the FDA.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$